Education
About Us
Working with TipRanks
Follow Us
OncoSil Medical Ltd (AU:OSL)
ASX:OSL
OSL Stock Chart & Stats
AU$0.97
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.97
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.69 - AU$2.09
Previous CloseN/A
Volume350.23K
Average Volume (3M)24.03K
Market Cap
AU$13.34M
Enterprise ValueAU$8.37M
Total Cash (Recent Filing)AU$5.11M
Total Debt (Recent Filing)AU$69.92K
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Mar 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.71
Shares Outstanding18,892,275
10 Day Avg. Volume8,764
30 Day Avg. Volume24,029
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)4.23
Price to Sales (P/S)11.20
P/FCF Ratio-1.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low debt relative to equity gives OncoSil financial flexibility to fund clinical programs, regulatory work, or commercialization without immediate heavy interest burdens. Over 2–6 months this reduces insolvency risk and preserves optionality for partnerships or targeted capital raises.
Revenue GrowthSustained top-line growth demonstrates emerging market adoption for the OncoSil device. If the company converts this growth into continued procedure volumes and wider clinical acceptance, revenue momentum supports scaling and helps justify further investment in commercialization and clinical evidence.
Niche, Clinically Focused ProductA specialized device addressing locally advanced pancreatic cancer creates a clear clinical niche and differentiation versus broad surgical or systemic therapies. Durable demand can arise from physician-led adoption, clinical guideline inclusion, and limited direct competition in targeted brachytherapy.
Bears Say
Negative ProfitabilityPersistent unprofitability and deeply negative operating margins indicate the business has not yet achieved unit economics needed for self-sustaining growth. Over months this pressures cash, forces cost control, and increases dependency on external funding or dilutive capital events to continue operations.
Negative Cash FlowsOngoing negative operating and free cash flow signals cash burn from operations and clinical/commercial activities. This structural cash gap requires timely financing or partnerships, raising execution risk and potential dilution which materially affects long-term strategic options.
Very Small WorkforceAn extremely small employee base constrains the company's ability to scale manufacturing, regulatory submissions, sales, and customer support in a capital-efficient manner. Reliance on external partners or contractors raises execution and coordination risk during commercialization and trials.
OncoSil Medical Ltd News
OSL FAQ
What was OncoSil Medical Ltd’s price range in the past 12 months?
OncoSil Medical Ltd lowest share price was AU$0.69 and its highest was AU$2.09 in the past 12 months.
What is OncoSil Medical Ltd’s market cap?
OncoSil Medical Ltd’s market cap is AU$13.34M.
When is OncoSil Medical Ltd’s upcoming earnings report date?
OncoSil Medical Ltd’s upcoming earnings report date is Mar 04, 2026 which is in 27 days.
How were OncoSil Medical Ltd’s earnings last quarter?
OncoSil Medical Ltd released its earnings results on Aug 28, 2025. The company reported -AU$0.707 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.707.
Is OncoSil Medical Ltd overvalued?
According to Wall Street analysts OncoSil Medical Ltd’s price is currently Overvalued.
Does OncoSil Medical Ltd pay dividends?
OncoSil Medical Ltd does not currently pay dividends.
What is OncoSil Medical Ltd’s EPS estimate?
OncoSil Medical Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OncoSil Medical Ltd have?
OncoSil Medical Ltd has 18,892,275 shares outstanding.
What happened to OncoSil Medical Ltd’s price movement after its last earnings report?
OncoSil Medical Ltd reported an EPS of -AU$0.707 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.679%.
Which hedge fund is a major shareholder of OncoSil Medical Ltd?
Currently, no hedge funds are holding shares in AU:OSL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
OncoSil Medical Ltd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:OSL Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
―
20 days / 200 days
Momentum
-67.40%
12-Months-Change
Fundamentals
Return on Equity
-385.20%
Trailing 12-Months
Asset Growth
6.40%
Trailing 12-Months
Company Description
OncoSil Medical Ltd
OncoSil Medical Limited, a medical device company, focuses on the development and commercialization of localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in worldwide. Its lead product is OncoSil, a brachytherapy device indicated for the treatment of patients with locally advanced unresectable pancreatic cancer, in combination with gemcitabine-based chemotherapy. The company was formerly known as NeuroDiscovery Limited and changed its name to OncoSil Medical Limited in May 2013. OncoSil Medical Limited was incorporated in 2005 and is headquartered in North Sydney, Australia.
Technical Analysis
Cyclopharm Limited
―
Micro-X Ltd.
―
EMvision Medical Devices Ltd.
―
Control Bionics Ltd.
―
4DMedical Ltd
―